Skip to main content
. Author manuscript; available in PMC: 2018 Apr 12.
Published in final edited form as: N Engl J Med. 2017 Oct 12;377(15):1438–1447. doi: 10.1056/NEJMoa1614067

Figure 1. Targeted Symptoms Reported at Week 1.

Figure 1

Shown are the percentages of participants who reported the indicated symptom at the week 1 visit in the placebo group, in the group that received the recombinant vesicular stomatitis virus–based vaccine (rVSVΔG-ZEBOV-GP), and in the group that received the chimpanzee adenovirus 3–based vaccine (ChAd3-EBO-Z). Symptoms are ordered according to the frequency with which they were reported by participants in the placebo group. Symptoms were prespecified in a checklist (i.e., targeted) at the week 1 visit.